Transfusion and COVID-19

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05075915

Acronym

TRANSCOV-19

Enrollment

500

Registered

2021-10-13

Start date

2020-09-01

Completion date

2021-12-31

Last updated

2021-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, Blood donation, Blood transfusion, Labile products, Blood platelets, Psoralen, ECMO, SARS-CoV-2, Consumption of blood products

Brief summary

Alsace was particularly and early on affected by SARS-CoV-2 and quickly implemented a reduction in scheduled admissions and non-urgent surgical interventions, making it possible to reduce requests for labile blood products linked to non-urgent surgical procedures. as has been reported in the literature; the population containment measures also led to a major reduction in traffic - and consequently accidents on the public roads. At the same time, other demands for blood products related to activities such as onco-hematology were little affected. Finally, the blood banks have adapted their collection procedure. To answer these questions, we propose to conduct a retrospective study over two parallel periods of 2019 and 2020 of the consumption of blood products on the one hand and the availability of stocks on the other hand.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults patient (≥18 years old) * Patients admitted to Strasbourg University Hospitals for suspicion of Covid-19, between February 24 and May 31 of 2019 and 2020 * Labile blood products consumed between February 24 and May 31 of 2019 and 2020 * Subjects not having his opposition, after information, to the reuse of his data for the purposes of this research. Non-inclusion criteria: * Patients who expressed opposition to participating in the study * Patients under legal protection * Patients under guardianship or curatorship

Design outcomes

Primary

Measure	Time frame
Study of the consumption of labile blood products at Strasbourg University Hospitals, during the two covid-19 periods: from February 24 to May 31, 2019 and 2020	Files analysed retrospectively from from February 24 to May 31, 2019 and from February 24 to May 31, 2020 will be examined]

Countries

France

Contacts

Primary ContactPaul-Michel MERTES, MD, PhD

paul-michel.mertes@chru-strasbourg.fr33 3 69 55 04 44

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr

Outcome results